MedTrace Logo

Assessing the Ability of the T-SPOT®.TB Test (IQ)

NCT03973970 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 201

Last updated 2021-02-24

No results posted yet for this study

Summary

The primary objective of this clinical research study is to demonstrate performance of the normalized TB specific lymphocyte response (NTBSLR) in identifying patients with active TB disease. The secondary exploratory objective is to demonstrate that active TB cannot be identified using an antigen-to-mitogen ratio derived from an ELISA-based IGRA.

Conditions

Sponsors & Collaborators

  • Oxford Immunotec

    lead INDUSTRY

Principal Investigators

  • Blanca Restrepo, MD · UTHealth Houston, School of Public Health

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-23
Primary Completion
2020-06-30
Completion
2020-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03973970 on ClinicalTrials.gov